Enifer pushes PEKILO into FDA review as it gears up for U.S. scale and supply deals

Finnish biotech company Enifer has moved its flagship mycoprotein ingredient, PEKILO, into formal review with the US Food and Drug Administration (FDA), marking a step forward in its efforts to secure large-scale commercial partnerships in one of the world’s most competitive ingredient markets.

• Enifer has submitted a notified GRAS dossier to the FDA for its PEKILO mycoprotein ingredient, following a self-affirmed GRAS determination completed in 2025.
• The company has reported that PEKILO contains up to 50% protein and 35% fiber and is designed as a shelf-stable, fermentation-derived ingredient for industrial food applications.
• Enifer has advanced regulatory submissions across multiple regions, including the USA, EU, UK, and Singapore, while scaling production capacity in Finland ahead of commercial rollout.

The submission builds on Enifer’s 2025 self-affirmed GRAS status and brings the ingredient into the FDA’s notified review process, with the company seeking a 'no questions' letter that would remove a key hurdle for large US food manufacturers evaluating new ingredients.

The move comes at a time when the alternative protein sector has shifted from early-stage experimentation to a more commercially focused phase, where regulatory clarity, consistent supply, and operational fit are becoming decisive factors in ingredient adoption.

Elisa Arte, Head of Food R&D at Enifer, said the FDA submission reflects the realities of how large manufacturers assess new inputs. “Large food manufacturers operate within strict procurement and compliance frameworks. FDA-notified GRAS status removes a key internal barrier, allowing ingredient discussions to move beyond technical sampling into long-term supply planning. At the same time, we are scaling production to ensure consistent, industrial volumes. In a market that has moved past hype and is now focused on unit economics and reliable capacity, regulatory clarity and manufacturing readiness must advance together. This step brings PEKILO into that commercial decision framework.”

Enifer develops its mycoprotein ingredients using a proprietary fermentation process originally pioneered in Finland, converting food and agricultural side streams into a dry, shelf-stable powder. PEKILO is designed to function as a versatile ingredient across multiple categories, including meat and dairy alternatives, hybrid products, snacks, and baked goods.

The ingredient contains up to 50% protein and 35% fiber, with a neutral taste and color that allows it to be incorporated into existing formulations without altering sensory profiles. That drop-in functionality has become increasingly important as manufacturers look for ingredients that can meet nutritional targets without introducing formulation complexity.

Simo Ellilä, CEO & Co-founder of Enifer, said the company has aligned its regulatory and production timelines to match how manufacturers approach long-term supply decisions. “Demand for protein isn’t slowing, but manufacturers are rethinking where that protein comes from and how it performs in finished products,” he said. “With regulatory review underway and our 2026 production ramp-up approaching, we are aligning capacity and compliance to support structured, long-term supply relationships in the US market.”

That alignment reflects a broader shift in how companies are approaching market entry. While Enifer already has the ability to enter the U.S. market through self-GRAS status, the company has pursued FDA notification in parallel to strengthen its commercial positioning.

Ellilä said this dual-track approach is part of a wider regulatory strategy that spans multiple regions. “Enifer has authorization to enter the US market via self-GRAS status, and work to obtain a ‘no questions’ letter from the FDA is underway. At the same time, dossiers have been submitted to regulators in Singapore, the UK, and the EU. This reflects our deliberate strategy to build market access in parallel across key regions. At Enifer, we see regulation not as a barrier, but as a necessary foundation for building trust in new food technologies. That said, the pace and predictability of regulatory processes matter significantly.”

The company’s focus on the US market is driven not only by regulatory access but also by the pace of innovation and openness to new ingredients. Ellilä pointed to evolving consumer and manufacturer expectations as key drivers.

“The US market is increasingly shaped by demand for foods that are nutritionally dense, support gut health, and meet clean-label expectations, while price and taste remain key factors,” he said. “Convenience also matters, both for consumers and for manufacturers looking to respond to these preferences at scale. Enifer’s flagship mycoprotein ingredient, PEKILO, is well positioned in that environment because it offers strong protein content, fiber, and clean-label potential in formats that can support more nutritious everyday products. For Enifer we see USA as an interesting market for us, not only because of the regulatory clearance but also because in the market there is openness to new ingredients and the speed of innovation offers faster routes to consumers with our ingredient.”

At the same time, the company has emphasized that regulatory approval alone is not enough to secure adoption. Instead, it is building its commercial strategy around the practical realities of procurement and manufacturing.

“We understand that entering the US market requires more than regulatory clearance,” Ellilä said. “It also requires a commercial approach that reflects how food manufacturers actually evaluate new ingredients: through procurement fit, operational feasibility, legal clarity, and long-term supply confidence. We are shaping Enifer’s market entry strategy accordingly, with a focus on practical execution and scalable partnerships.”

That focus on supply reliability is tied closely to Enifer’s production plans. The company is currently scaling up its first commercial facility in Kantvik, Finland, which is expected to be completed in late 2026. Beyond that, it is already considering additional facilities to expand capacity over time.

“Enifer’s goal is to work with food companies of different sizes that want to develop nutritious products for their customers,” Ellilä said. “With our first factory in Kantvik, Finland expected to be completed in late 2026, we are already looking ahead to additional facilities that would expand supply capacity over time. And this is a general shift, where startups are moving into scaleups and from pilots to productions, compelling stories matter – alongside matters delivering reliability at scale. Customers are looking beyond just innovation to partnerships who can ensure consistency.”

This transition from pilot-scale innovation to industrial production is becoming a defining feature of the alternative protein ingredient sector. As the market matures, companies are increasingly judged not on technical novelty but on their ability to integrate into existing food systems.

Ellilä described this as a broader turning point for the category. “We see the alternative protein ingredient market entering a more grounded and demanding phase,” he said. “The conversation is shifting away from novelty and broad promises, and toward whether an ingredient can deliver in real commercial conditions. That means fitting into existing production systems, meeting clear nutritional goals, supporting clean-label expectations, and offering a credible path to scale. We believe this shift favors companies that are building for long-term adoption rather than short-term attention.”

Within that context, fermentation-derived ingredients such as mycoprotein are gaining traction, particularly where they offer a combination of scalability and functional versatility.

“We see that fermentation derived ingredients, like mycoproteins e.g. PEKILO are gaining traction because they offer a combination of proven technology, industrial scalability and versatility in final consumer facing applications,” Ellilä said.

With FDA review underway and production scaling in parallel, Enifer is now moving into a phase where regulatory progress, manufacturing readiness, and commercial engagement are advancing together. The company expects the FDA process to continue throughout 2026 as it deepens discussions with food manufacturers across multiple categories in the U.S.